170 related articles for article (PubMed ID: 18182077)
1. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.
Mylin AK; Abildgaard N; Johansen JS; Andersen NF; Heickendorff L; Standal T; Gimsing P; Knudsen LM
Eur J Haematol; 2008 Apr; 80(4):310-7. PubMed ID: 18182077
[TBL] [Abstract][Full Text] [Related]
2. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
[TBL] [Abstract][Full Text] [Related]
3. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.
Mylin AK; Abildgaard N; Johansen JS; Heickendorff L; Kreiner S; Waage A; Turesson I; Gimsing P;
Leuk Lymphoma; 2015; 56(9):2650-9. PubMed ID: 25573204
[TBL] [Abstract][Full Text] [Related]
4. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.
Nordenbaek C; Johansen JS; Halberg P; Wiik A; Garbarsch C; Ullman S; Price PA; Jacobsen S
Scand J Rheumatol; 2005; 34(4):293-7. PubMed ID: 16195162
[TBL] [Abstract][Full Text] [Related]
5. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
Johansen JS; Brasso K; Iversen P; Teisner B; Garnero P; Price PA; Christensen IJ
Clin Cancer Res; 2007 Jun; 13(11):3244-9. PubMed ID: 17545529
[TBL] [Abstract][Full Text] [Related]
6. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
[TBL] [Abstract][Full Text] [Related]
7. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
[TBL] [Abstract][Full Text] [Related]
8. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
[TBL] [Abstract][Full Text] [Related]
9. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
[TBL] [Abstract][Full Text] [Related]
10. Serum YKL-40 and colorectal cancer.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Br J Cancer; 1999 Mar; 79(9-10):1494-9. PubMed ID: 10188896
[TBL] [Abstract][Full Text] [Related]
11. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV; Johansen JS; Price PA
Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
[TBL] [Abstract][Full Text] [Related]
12. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
13. N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.
Mylin AK; Goetze JP; Heickendorff L; Ahlberg L; Dahl IM; Abildgaard N; Gimsing P;
Biomark Med; 2015; 9(7):679-89. PubMed ID: 26174842
[TBL] [Abstract][Full Text] [Related]
14. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease.
Erzin Y; Uzun H; Karatas A; Celik AF
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e357-62. PubMed ID: 17725598
[TBL] [Abstract][Full Text] [Related]
15. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction.
Johansen JS; Kirwan JR; Price PA; Sharif M
Scand J Rheumatol; 2001; 30(5):297-304. PubMed ID: 11727845
[TBL] [Abstract][Full Text] [Related]
16. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
[TBL] [Abstract][Full Text] [Related]
17. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
[TBL] [Abstract][Full Text] [Related]
18. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.
Zheng JL; Lu L; Hu J; Zhang RY; Zhang Q; Chen QJ; Shen WF
Atherosclerosis; 2010 Jun; 210(2):590-5. PubMed ID: 20056225
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of YKL-40 increases in patients with acute myocardial infarction.
Nøjgaard C; Høst NB; Christensen IJ; Poulsen SH; Egstrup K; Price PA; Johansen JS
Coron Artery Dis; 2008 Jun; 19(4):257-63. PubMed ID: 18480670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
